董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| William Plovanic | 男 | Independent Director | 56 | 3.63万美元 | 2.68 | 2025-10-31 |
| Kurt Azarbarzin | 男 | Director | 63 | 8.48万美元 | 未持股 | 2025-10-31 |
| Vince Burgess | 男 | Director | 61 | 8.73万美元 | 未持股 | 2025-10-31 |
| Federica O'Brien | 女 | Director | 67 | 9.23万美元 | 未持股 | 2025-10-31 |
| Doug Evans | 男 | Director and Chairman of the Board | 60 | 12.65万美元 | 未持股 | 2025-10-31 |
| Betty Jo Rocchio | -- | Director | 57 | 4.36万美元 | 0.59 | 2025-10-31 |
| William Plovanic | 男 | Independent Director | 56 | 未披露 | 未持股 | 2025-10-31 |
| Antony Koblish | 男 | Director and Chief Executive Officer | 59 | 196.96万美元 | 177.63 | 2025-10-31 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jeffrey Blizard | 男 | President | 56 | 95.27万美元 | 9.77 | 2025-10-31 |
| Paul Talmo | 男 | Chief Technology Officer | 58 | 81.66万美元 | 未持股 | 2025-10-31 |
| Antony Koblish | 男 | Director and Chief Executive Officer | 59 | 196.96万美元 | 177.63 | 2025-10-31 |
| Roberto Cuca | 男 | Chief Operating Officer and Chief Financial Officer | 57 | 103.59万美元 | 39.05 | 2025-10-31 |
董事简历
中英对照 | 中文 | 英文- William Plovanic
-
William Plovanic自2019年5月任职起担任I类董事。Plovanic先生目前是投资银行Canaccord Genuity Inc.的股票研究部门董事总经理。此前，Plovanic先生于2019年10月至2020年6月担任首席执行官。Plovanic先生还于2016年3月至2019年10月期间担任首席财务官。此前，Plovanic先生于2007年2月至2016年3月在Canaccord Genuity Inc.担任医疗技术股票研究董事总经理。在加入Canaccord Genuity之前，Plovanic先生曾于2001年2月至2007年2月在First Albany Capital Inc.担任多个职务，包括担任Equity Research董事总经理。Plovanic先生拥有Bradley大学的学士学位，并且是CFA特许持有人。
William Plovanic has served as a Class I director since his appointment in May 2019. Mr. Plovanic is currently Managing Director, Equity Research at Canaccord Genuity Inc., an investment bank. Previously, Mr. Plovanic served as Chief Executive Officer from October 2019 to June 2020. Mr. Plovanic has also served Chief Financial Officer from March 2016 to October 2019. Previously, Mr. Plovanic served as Managing Director, Medical Technology Equity Research at Canaccord Genuity Inc. from February 2007 to March 2016. Prior to Canaccord Genuity, Mr. Plovanic served in various roles at First Albany Capital Inc. from February 2001 to February 2007 including as Managing Director, Equity Research. Mr. Plovanic holds a B.S. from Bradley University and is a CFA Charterholder. - William Plovanic自2019年5月任职起担任I类董事。Plovanic先生目前是投资银行Canaccord Genuity Inc.的股票研究部门董事总经理。此前，Plovanic先生于2019年10月至2020年6月担任首席执行官。Plovanic先生还于2016年3月至2019年10月期间担任首席财务官。此前，Plovanic先生于2007年2月至2016年3月在Canaccord Genuity Inc.担任医疗技术股票研究董事总经理。在加入Canaccord Genuity之前，Plovanic先生曾于2001年2月至2007年2月在First Albany Capital Inc.担任多个职务，包括担任Equity Research董事总经理。Plovanic先生拥有Bradley大学的学士学位，并且是CFA特许持有人。
- William Plovanic has served as a Class I director since his appointment in May 2019. Mr. Plovanic is currently Managing Director, Equity Research at Canaccord Genuity Inc., an investment bank. Previously, Mr. Plovanic served as Chief Executive Officer from October 2019 to June 2020. Mr. Plovanic has also served Chief Financial Officer from March 2016 to October 2019. Previously, Mr. Plovanic served as Managing Director, Medical Technology Equity Research at Canaccord Genuity Inc. from February 2007 to March 2016. Prior to Canaccord Genuity, Mr. Plovanic served in various roles at First Albany Capital Inc. from February 2001 to February 2007 including as Managing Director, Equity Research. Mr. Plovanic holds a B.S. from Bradley University and is a CFA Charterholder.
- Kurt Azarbarzin
-
Kurt Azarbarzin自2018年11月以来一直是我们的董事会成员。Azarbarzin先生自2019年7月起担任机器人手术公司Verb Surgical Inc.的首席执行官兼董事会成员。Azarbarzin先生曾于2016年至2019年7月担任Conmed Corporation的首席技术官，该公司是一家致力于帮助客户改善患者预后的全球上市医疗设备公司。Azarbarzin先生是Surgiquest，Inc.的前任创始人，该公司是一家专注于推进微创手术的医疗设备公司，并于2005年至2016年6月担任其首席执行官。Azarbarzin先生是耶鲁大学生物医学创新与技术中心（Center for Biomedical Innovation and Technology）的执行董事会成员。Azarbarzin先生曾在U.S.Surgical&Tyco梦百合担任研究与开发方面的领导职务。他在布里奇波特大学（University of Bridgeport）获得理学学士学位，并在布里奇波特工程学院（Bridgeport Engineering Institute）完成机械设计高级研究生学习，在布拉德利大学（Bradley University）完成制造工程。
Kurt Azarbarzin,has been a member of Board since November 2018. Mr. Azarbarzin previously served as the Chief Executive Officer and a member of the board of Endoquest Robotics, a medical device company that designs and develops flexible microsurgical robotic devices, from November 2020 until June 2024. Mr. Azarbarzin served as Chief Executive Officer and a member of the board of directors of Verb Surgical Inc., a robotic surgery company, from July 2019 to November 2020. Mr. Azarbarzin previously served as Chief Technology Officer for CONMED Corporation, a global, publicly-traded medical device company dedicated to helping customers improve patient outcomes, from 2016 to July 2019. Mr. Azarbarzin is the former Founder of SurgiQuest, Inc., a medical device company focused on advancing minimally invasive surgery, and served as its Chief Executive Officer from 2005 until June 2016. Mr. Azarbarzin is a member of the executive board at Center for Biomedical Innovation and Technology at Yale University. Mr. Azarbarzin previously held leadership roles in Research and Development at U.S. Surgical & Tyco Healthcare. He earned a Bachelor of Science from the University of Bridgeport. - Kurt Azarbarzin自2018年11月以来一直是我们的董事会成员。Azarbarzin先生自2019年7月起担任机器人手术公司Verb Surgical Inc.的首席执行官兼董事会成员。Azarbarzin先生曾于2016年至2019年7月担任Conmed Corporation的首席技术官，该公司是一家致力于帮助客户改善患者预后的全球上市医疗设备公司。Azarbarzin先生是Surgiquest，Inc.的前任创始人，该公司是一家专注于推进微创手术的医疗设备公司，并于2005年至2016年6月担任其首席执行官。Azarbarzin先生是耶鲁大学生物医学创新与技术中心（Center for Biomedical Innovation and Technology）的执行董事会成员。Azarbarzin先生曾在U.S.Surgical&Tyco梦百合担任研究与开发方面的领导职务。他在布里奇波特大学（University of Bridgeport）获得理学学士学位，并在布里奇波特工程学院（Bridgeport Engineering Institute）完成机械设计高级研究生学习，在布拉德利大学（Bradley University）完成制造工程。
- Kurt Azarbarzin,has been a member of Board since November 2018. Mr. Azarbarzin previously served as the Chief Executive Officer and a member of the board of Endoquest Robotics, a medical device company that designs and develops flexible microsurgical robotic devices, from November 2020 until June 2024. Mr. Azarbarzin served as Chief Executive Officer and a member of the board of directors of Verb Surgical Inc., a robotic surgery company, from July 2019 to November 2020. Mr. Azarbarzin previously served as Chief Technology Officer for CONMED Corporation, a global, publicly-traded medical device company dedicated to helping customers improve patient outcomes, from 2016 to July 2019. Mr. Azarbarzin is the former Founder of SurgiQuest, Inc., a medical device company focused on advancing minimally invasive surgery, and served as its Chief Executive Officer from 2005 until June 2016. Mr. Azarbarzin is a member of the executive board at Center for Biomedical Innovation and Technology at Yale University. Mr. Azarbarzin previously held leadership roles in Research and Development at U.S. Surgical & Tyco Healthcare. He earned a Bachelor of Science from the University of Bridgeport.
- Vince Burgess
-
Vince Burgess自2017年10月起担任我们的总裁兼首席执行官，自2013年6月起担任我们的董事会成员。2010年9月至2020年6月，Burgess先生还担任OrbiMed Advisors（一家专注于梦百合行业的投资公司）的风险合伙人。从2002年到2010年，伯吉斯先生在Volcano Corporation担任多个领导职位，他是该公司创始团队的一员。他也任职于多家私人医疗技术公司的董事会。Burgess先生在南加州大学（University of Southern California）获得工商管理与创业学士学位，并在加州大学洛杉矶分校（University of California，Los Angeles）获得工商管理硕士学位。
Vince Burgess,has been a member of Board since June 2014. From October 2017 until his retirement in May 2022, Mr. Burgess served as President, Chief Executive Officer and member of the board of directors of Acutus Medical, Inc., a medical device company, and previously served as a Venture Partner with OrbiMed Advisors, LLC, a healthcare investment firm, from September 2011 until May 2020. Previously, Mr. Burgess was a member of the initial executive team at Volcano Corporation, where he served as President of Advanced Imaging Systems. He also led marketing and business development at Volcano from 2002 to 2010. He previously served as a member of the board of directors of Bolt Medical until its acquisition by Boston Scientific. He has previously served on the boards of NeuroPace, Inc., Sonendo Inc., Ornim Medical, Keystone Heart, Inc., Vessix Vasular, Cryterion Medical and CardiAQ, Inc. He earned his Bachelor of Science degree in Business Administration from the University of Southern California and his Masters of Business Administration from the University of California, Los Angeles. - Vince Burgess自2017年10月起担任我们的总裁兼首席执行官，自2013年6月起担任我们的董事会成员。2010年9月至2020年6月，Burgess先生还担任OrbiMed Advisors（一家专注于梦百合行业的投资公司）的风险合伙人。从2002年到2010年，伯吉斯先生在Volcano Corporation担任多个领导职位，他是该公司创始团队的一员。他也任职于多家私人医疗技术公司的董事会。Burgess先生在南加州大学（University of Southern California）获得工商管理与创业学士学位，并在加州大学洛杉矶分校（University of California，Los Angeles）获得工商管理硕士学位。
- Vince Burgess,has been a member of Board since June 2014. From October 2017 until his retirement in May 2022, Mr. Burgess served as President, Chief Executive Officer and member of the board of directors of Acutus Medical, Inc., a medical device company, and previously served as a Venture Partner with OrbiMed Advisors, LLC, a healthcare investment firm, from September 2011 until May 2020. Previously, Mr. Burgess was a member of the initial executive team at Volcano Corporation, where he served as President of Advanced Imaging Systems. He also led marketing and business development at Volcano from 2002 to 2010. He previously served as a member of the board of directors of Bolt Medical until its acquisition by Boston Scientific. He has previously served on the boards of NeuroPace, Inc., Sonendo Inc., Ornim Medical, Keystone Heart, Inc., Vessix Vasular, Cryterion Medical and CardiAQ, Inc. He earned his Bachelor of Science degree in Business Administration from the University of Southern California and his Masters of Business Administration from the University of California, Los Angeles.
- Federica O'Brien
-
FedericaO’Brien将在本招股说明书所包含的注册声明生效后立即加入我们的董事会。O’Brien女士自2018年1月起担任CFO’Brien Consulting，LLC的总裁，主要为生物技术公司提供C-Suite级别的咨询。此前，她曾于2015年5月至2017年12月担任生物制药公司Complexa Inc.的首席财务官，并于2013年4月至2015年5月担任生物制药公司Cerecor公司的首席财务官。在此之前，O’Brien女士于2011年6月至2013年4月担任私人医疗设备公司Cervilenz Inc.的首席财务官兼首席运营官，并于2010年2月至2011年5月担任独立会计师事务所McGladrey LLP的生命科学总监。从2009年7月到2010年2月，O’Brien女士提供财务和战略咨询服务。2005年4月至2009年7月，O’Brien女士担任Cardiokine Inc.（一家私营生物技术公司）的首席财务官。2005年之前，在生物技术公司首次公开募股期间和之后，O’Brien女士担任Barrier Therapeutics的财务总监，并担任Infonautics，Inc.（当时是一家公开上市的技术公司）的首席财务官。她的职业生涯始于任职公共会计师事务所，包括最近担任Coopers&Lybrand公司的审计经理。O’Brien女士在罗格斯大学（Rutgers University）获得会计学学士学位，是新泽西州的注册会计师。
Federica O'Brien,has been a member of Board since November 2019. Ms. O'Brien has been the President of CFO'Brien Consulting, LLC since January of 2018 providing strategic, operational and financial consulting, and flexible time Chief Financial Officer services primarily for biotech companies. Previously she served as Chief Financial Officer of Complexa Inc., a biopharmaceutical company, from May 2015 to December 2017 and as Chief Financial Officer of Cerecor Inc., a biopharmaceutical company, from April 2013 to May 2015. Prior to that, Ms. O'Brien served as the Chief Financial Officer and Chief Operating Officer of Cervilenz Inc., a privately held medical device company, from June 2011 through April 2013. She has also held senior financial management positions at Cardiokine Inc., a privately held biotechnology company, Barrier Therapeutics, Inc., during and subsequent to the biotechnology company's initial public offering, and at Infonautics, Inc., then a publicly held technology company. Ms. O'Brien currently serves on the board of directors and chairs the audit committee for MacroGenics, Inc., a biopharmaceutical company. She began her career at public accounting firms including most recently as an Audit Manager for Coopers & Lybrand. Ms. O'Brien received her B.A. in Accounting from Rutgers University and is a Certified Public Accountant—Inactive in the State of New Jersey. - FedericaO’Brien将在本招股说明书所包含的注册声明生效后立即加入我们的董事会。O’Brien女士自2018年1月起担任CFO’Brien Consulting，LLC的总裁，主要为生物技术公司提供C-Suite级别的咨询。此前，她曾于2015年5月至2017年12月担任生物制药公司Complexa Inc.的首席财务官，并于2013年4月至2015年5月担任生物制药公司Cerecor公司的首席财务官。在此之前，O’Brien女士于2011年6月至2013年4月担任私人医疗设备公司Cervilenz Inc.的首席财务官兼首席运营官，并于2010年2月至2011年5月担任独立会计师事务所McGladrey LLP的生命科学总监。从2009年7月到2010年2月，O’Brien女士提供财务和战略咨询服务。2005年4月至2009年7月，O’Brien女士担任Cardiokine Inc.（一家私营生物技术公司）的首席财务官。2005年之前，在生物技术公司首次公开募股期间和之后，O’Brien女士担任Barrier Therapeutics的财务总监，并担任Infonautics，Inc.（当时是一家公开上市的技术公司）的首席财务官。她的职业生涯始于任职公共会计师事务所，包括最近担任Coopers&Lybrand公司的审计经理。O’Brien女士在罗格斯大学（Rutgers University）获得会计学学士学位，是新泽西州的注册会计师。
- Federica O'Brien,has been a member of Board since November 2019. Ms. O'Brien has been the President of CFO'Brien Consulting, LLC since January of 2018 providing strategic, operational and financial consulting, and flexible time Chief Financial Officer services primarily for biotech companies. Previously she served as Chief Financial Officer of Complexa Inc., a biopharmaceutical company, from May 2015 to December 2017 and as Chief Financial Officer of Cerecor Inc., a biopharmaceutical company, from April 2013 to May 2015. Prior to that, Ms. O'Brien served as the Chief Financial Officer and Chief Operating Officer of Cervilenz Inc., a privately held medical device company, from June 2011 through April 2013. She has also held senior financial management positions at Cardiokine Inc., a privately held biotechnology company, Barrier Therapeutics, Inc., during and subsequent to the biotechnology company's initial public offering, and at Infonautics, Inc., then a publicly held technology company. Ms. O'Brien currently serves on the board of directors and chairs the audit committee for MacroGenics, Inc., a biopharmaceutical company. She began her career at public accounting firms including most recently as an Audit Manager for Coopers & Lybrand. Ms. O'Brien received her B.A. in Accounting from Rutgers University and is a Certified Public Accountant—Inactive in the State of New Jersey.
- Doug Evans
-
Doug Evans，自2020年4月起担任董事会成员。Evans先生自2014年1月起担任医疗设备公司Lungpacer Medical Inc.的总裁兼首席执行官。在加入Lungpacer之前，Evans先生于1995年3月至2012年5月期间担任医疗器械公司肯瑟-纳斯医疗的首席运营官和董事会成员。埃文斯先生目前担任WhiteSwell Medical和Lungpacer Medical，Inc.的董事会成员，这两家公司都是医疗设备公司。埃文斯此前曾在Intact Vascular，Inc.董事会任职，该公司是一家私营医疗设备公司。Evans先生拥有宾夕法尼亚大学电气工程和光子学理学硕士学位、宾夕法尼亚州立大学大山谷研究生专业研究学院工商管理硕士学位和宾夕法尼亚州立大学工程科学理学学士学位。
Doug Evans,has been a member of Board since April 2020. Mr. Evans has served as the President and Chief Executive Officer of Lungpacer Medical Inc., a medical device company, since January 2014. Prior to joining Lungpacer, Mr. Evans served as the Chief Operating Officer and a member of the board of directors of Kensey Nash Corporation, a medical device company, from March 1995 to May 2012. Mr. Evans currently serves on the board of directors of WhiteSwell Medical and Lungpacer Medical, Inc., both medical device companies. Mr. Evans previously served on the board of Intact Vascular, Inc., a privately held medical device company. Mr. Evans holds a Master of Science degree in Electrical Engineering and Photonics from the University of Pennsylvania, a M.B.A. from Pennsylvania State University Great Valley School of Graduate Professional Studies and a Bachelor of Science in Engineering Sciences from the Pennsylvania State University. - Doug Evans，自2020年4月起担任董事会成员。Evans先生自2014年1月起担任医疗设备公司Lungpacer Medical Inc.的总裁兼首席执行官。在加入Lungpacer之前，Evans先生于1995年3月至2012年5月期间担任医疗器械公司肯瑟-纳斯医疗的首席运营官和董事会成员。埃文斯先生目前担任WhiteSwell Medical和Lungpacer Medical，Inc.的董事会成员，这两家公司都是医疗设备公司。埃文斯此前曾在Intact Vascular，Inc.董事会任职，该公司是一家私营医疗设备公司。Evans先生拥有宾夕法尼亚大学电气工程和光子学理学硕士学位、宾夕法尼亚州立大学大山谷研究生专业研究学院工商管理硕士学位和宾夕法尼亚州立大学工程科学理学学士学位。
- Doug Evans,has been a member of Board since April 2020. Mr. Evans has served as the President and Chief Executive Officer of Lungpacer Medical Inc., a medical device company, since January 2014. Prior to joining Lungpacer, Mr. Evans served as the Chief Operating Officer and a member of the board of directors of Kensey Nash Corporation, a medical device company, from March 1995 to May 2012. Mr. Evans currently serves on the board of directors of WhiteSwell Medical and Lungpacer Medical, Inc., both medical device companies. Mr. Evans previously served on the board of Intact Vascular, Inc., a privately held medical device company. Mr. Evans holds a Master of Science degree in Electrical Engineering and Photonics from the University of Pennsylvania, a M.B.A. from Pennsylvania State University Great Valley School of Graduate Professional Studies and a Bachelor of Science in Engineering Sciences from the Pennsylvania State University.
- Betty Jo Rocchio
-
Betty Jo Rocchio，自2024年11月起担任非营利性综合健康系统Advocate Health的执行副总裁兼首席执行护士。作为首席执行护士，Rocchio博士负责监督企业护理结构，该结构由16.5万名全职员工组成，其中包括4.2万名注册护士，是首席执行官内阁的在职成员。此前，Rocchio博士于2020年10月至2024年11月担任Mercy Health System（“Mercy”）的高级副总裁兼首席护士执行官。在Mercy，Rocchio博士分别于2013年7月至2018年3月和2018年4月至2020年10月担任系统副总裁、围手术期绩效加速和系统副总裁、首席护理优化官。Rocchio博士拥有斯图本维尔方济各会大学的护理学学士学位和商业管理副学士学位、拉罗什学院的Health Sciences硕士学位、圣弗朗西斯麻醉学院的麻醉证书以及俄亥俄州立大学的护理实践博士学位。
Betty Jo Rocchio,has served as the Executive Vice President, Chief Executive Nurse at Advocate Health, a nonprofit integrated health system, since November 2024. As Chief Executive Nurse, Dr. Rocchio oversees the enterprise nursing structure, which consists of 165,000 full time employees, including 42,000 registered nurses, and is a serving member of the CEO's cabinet. Previously, Dr. Rocchio served as the Senior Vice President, Chief Nurse Executive at Mercy Health System ("Mercy") from October 2020 to November 2024. At Mercy, Dr. Rocchio held additional roles of System Vice President, Perioperative Performance Acceleration and System Vice President, Chief Nursing Optimization Officer from July 2013 to March 2018 and April 2018 to October 2020, respectively. Dr. Rocchio holds a Bachelor's degree in Nursing and an Associate degree in Business Management from the Franciscan University of Steubenville, a Master's degree in Health Sciences from LaRoche College, a Certificate of Anesthesia from St. Francis School of Anesthesia, and a Doctorate of Nursing Practice from The Ohio State University. - Betty Jo Rocchio，自2024年11月起担任非营利性综合健康系统Advocate Health的执行副总裁兼首席执行护士。作为首席执行护士，Rocchio博士负责监督企业护理结构，该结构由16.5万名全职员工组成，其中包括4.2万名注册护士，是首席执行官内阁的在职成员。此前，Rocchio博士于2020年10月至2024年11月担任Mercy Health System（“Mercy”）的高级副总裁兼首席护士执行官。在Mercy，Rocchio博士分别于2013年7月至2018年3月和2018年4月至2020年10月担任系统副总裁、围手术期绩效加速和系统副总裁、首席护理优化官。Rocchio博士拥有斯图本维尔方济各会大学的护理学学士学位和商业管理副学士学位、拉罗什学院的Health Sciences硕士学位、圣弗朗西斯麻醉学院的麻醉证书以及俄亥俄州立大学的护理实践博士学位。
- Betty Jo Rocchio,has served as the Executive Vice President, Chief Executive Nurse at Advocate Health, a nonprofit integrated health system, since November 2024. As Chief Executive Nurse, Dr. Rocchio oversees the enterprise nursing structure, which consists of 165,000 full time employees, including 42,000 registered nurses, and is a serving member of the CEO's cabinet. Previously, Dr. Rocchio served as the Senior Vice President, Chief Nurse Executive at Mercy Health System ("Mercy") from October 2020 to November 2024. At Mercy, Dr. Rocchio held additional roles of System Vice President, Perioperative Performance Acceleration and System Vice President, Chief Nursing Optimization Officer from July 2013 to March 2018 and April 2018 to October 2020, respectively. Dr. Rocchio holds a Bachelor's degree in Nursing and an Associate degree in Business Management from the Franciscan University of Steubenville, a Master's degree in Health Sciences from LaRoche College, a Certificate of Anesthesia from St. Francis School of Anesthesia, and a Doctorate of Nursing Practice from The Ohio State University.
- William Plovanic
-
William Plovanic，自2020年5月起担任Canaccord Genuity LLC（“Canaccord”）医疗保健股票研究部门董事总经理，该公司是一家专注于成长型公司的全球投资银行。作为董事总经理，Plovanic先生领导医疗技术领域的股权研究覆盖，包括心血管、糖尿病和神经调节。在此之前，Plovanic先生曾于2016年3月在Obalon Therapeutics, Inc.（“Obalon”）（前身为纳斯达克：OBLN）担任总裁、首席执行官、首席财务官以及董事会成员，该公司此前是一家医疗器械上市公司，直至2021年6月与ReShape LifeSciences，Inc.（前身为纳斯达克：RSLS）合并。在Obalon，Plovanic先生指导公司完成了新型肥胖治疗技术和服务的商业化、重大的组织变革，以及最终与ReShape LifeSciences的合并。在加入Obalon之前，Plovanic先生曾担任股票研究分析师20年，覆盖骨科和生物材料领域的医疗技术公司。Plovanic先生拥有布拉德利大学金融学理学学士学位，并且是特许金融分析师（CFA）特许持有人。
William Plovanic,has served as Managing Director, Healthcare Equity Research at Canaccord Genuity LLC ("Canaccord"), a global investment bank focused on growth companies, since May 2020. As Managing Director, Mr. Plovanic leads equity research coverage of medical technology sectors, including cardiovascular, diabetes, and neuromodulation. Previously, Mr. Plovanic served as President, Chief Executive Officer, Chief Financial Officer, and as a board member at Obalon Therapeutics, Inc. ("Obalon") (formerly, Nasdaq: OBLN), a previously publicly traded medical device company, from March 2016 until a merger with ReShape LifeSciences, Inc. (formerly, Nasdaq: RSLS) in June 2021. At Obalon, Mr. Plovanic guided the company through commercialization of novel obesity treatment technologies and services, significant organizational changes, and its eventual merger with ReShape LifeSciences. Prior to Obalon, Mr. Plovanic worked as an equity research analyst for 20 years covering medical technology companies in the orthopedics and biomaterials sectors. Mr. Plovanic holds a Bachelor of Science in Finance from Bradley University and is a Chartered Financial Analyst (CFA) Charterholder. - William Plovanic，自2020年5月起担任Canaccord Genuity LLC（“Canaccord”）医疗保健股票研究部门董事总经理，该公司是一家专注于成长型公司的全球投资银行。作为董事总经理，Plovanic先生领导医疗技术领域的股权研究覆盖，包括心血管、糖尿病和神经调节。在此之前，Plovanic先生曾于2016年3月在Obalon Therapeutics, Inc.（“Obalon”）（前身为纳斯达克：OBLN）担任总裁、首席执行官、首席财务官以及董事会成员，该公司此前是一家医疗器械上市公司，直至2021年6月与ReShape LifeSciences，Inc.（前身为纳斯达克：RSLS）合并。在Obalon，Plovanic先生指导公司完成了新型肥胖治疗技术和服务的商业化、重大的组织变革，以及最终与ReShape LifeSciences的合并。在加入Obalon之前，Plovanic先生曾担任股票研究分析师20年，覆盖骨科和生物材料领域的医疗技术公司。Plovanic先生拥有布拉德利大学金融学理学学士学位，并且是特许金融分析师（CFA）特许持有人。
- William Plovanic,has served as Managing Director, Healthcare Equity Research at Canaccord Genuity LLC ("Canaccord"), a global investment bank focused on growth companies, since May 2020. As Managing Director, Mr. Plovanic leads equity research coverage of medical technology sectors, including cardiovascular, diabetes, and neuromodulation. Previously, Mr. Plovanic served as President, Chief Executive Officer, Chief Financial Officer, and as a board member at Obalon Therapeutics, Inc. ("Obalon") (formerly, Nasdaq: OBLN), a previously publicly traded medical device company, from March 2016 until a merger with ReShape LifeSciences, Inc. (formerly, Nasdaq: RSLS) in June 2021. At Obalon, Mr. Plovanic guided the company through commercialization of novel obesity treatment technologies and services, significant organizational changes, and its eventual merger with ReShape LifeSciences. Prior to Obalon, Mr. Plovanic worked as an equity research analyst for 20 years covering medical technology companies in the orthopedics and biomaterials sectors. Mr. Plovanic holds a Bachelor of Science in Finance from Bradley University and is a Chartered Financial Analyst (CFA) Charterholder.
- Antony Koblish
-
Antony Koblish，是联合创始人之一，自2012年4月创立以来一直担任总裁兼首席执行官和董事会成员。在此之前，Koblish先生是Orthovita医疗的总裁兼首席执行官，该公司是一家上市的骨科生物制剂和生物外科医疗器械公司。Koblish先生与他人共同创立并目前担任外科肿瘤公司Onkos Surgical，Inc.的董事会主席，并且是1315 Capital的运营合作伙伴，1315 Capital是一家私人投资公司，为商业阶段的专业制药、医疗技术和医疗保健服务公司提供扩张和增长资本。Koblish先生还担任私营骨科生物制剂公司Cerapedics Inc.的董事会成员，并且是Spineology，Inc.的董事会观察员，该公司是一家私营脊柱公司，也是1315 Capital的投资组合公司。作为Cerapedics的董事会成员、Spineology的观察员和Onkos Surgical的董事会主席，Koblish先生每季度分别参加一次董事会会议，作为1315 Capital的运营合伙人，Koblish先生每季度参加一到两次会议。Koblish先生剩余的时间专门用于担任首席执行官。Koblish先生获得宾夕法尼亚大学机械工程和应用力学工程学理学硕士学位，并拥有伍斯特理工学院机械工程学理学学士学位。
Antony Koblish,is one of co-founders and has served as President and Chief Executive Officer and as a member of the Board since founding in April 2012. Previously, Mr. Koblish was President and Chief Executive Officer of Orthovita, Inc., a publicly traded orthobiologics and biosurgery medical device company. Mr. Koblish co-founded and currently serves as Chairman of the Board of Onkos Surgical, Inc., a surgical oncology company, and is an operating partner with 1315 Capital, a private investment firm that provides expansion and growth capital to commercial-stage specialty pharmaceutical, medical technology, and health care services companies. Mr. Koblish also serves on the Board of Cerapedics Inc., a private ortho-biologics company, and is a board observer of Spineology, Inc., a private spine company and portfolio company of 1315 Capital. As a Board member of Cerapedics, observer of Spineology, and Chairman of the Board of Onkos Surgical, Mr. Koblish attends one board meeting per quarter, respectively, and as an operating partner for 1315 Capital Mr. Koblish attends one to two meetings per quarter. The remainder of Mr. Koblish's time is dedicated to serving as Chief Executive Officer. Mr. Koblish earned a Master of Science in Engineering degree in Mechanical Engineering and Applied Mechanics from the University of Pennsylvania, and holds a Bachelor of Science degree in Mechanical Engineering from Worcester Polytechnic Institute. - Antony Koblish，是联合创始人之一，自2012年4月创立以来一直担任总裁兼首席执行官和董事会成员。在此之前，Koblish先生是Orthovita医疗的总裁兼首席执行官，该公司是一家上市的骨科生物制剂和生物外科医疗器械公司。Koblish先生与他人共同创立并目前担任外科肿瘤公司Onkos Surgical，Inc.的董事会主席，并且是1315 Capital的运营合作伙伴，1315 Capital是一家私人投资公司，为商业阶段的专业制药、医疗技术和医疗保健服务公司提供扩张和增长资本。Koblish先生还担任私营骨科生物制剂公司Cerapedics Inc.的董事会成员，并且是Spineology，Inc.的董事会观察员，该公司是一家私营脊柱公司，也是1315 Capital的投资组合公司。作为Cerapedics的董事会成员、Spineology的观察员和Onkos Surgical的董事会主席，Koblish先生每季度分别参加一次董事会会议，作为1315 Capital的运营合伙人，Koblish先生每季度参加一到两次会议。Koblish先生剩余的时间专门用于担任首席执行官。Koblish先生获得宾夕法尼亚大学机械工程和应用力学工程学理学硕士学位，并拥有伍斯特理工学院机械工程学理学学士学位。
- Antony Koblish,is one of co-founders and has served as President and Chief Executive Officer and as a member of the Board since founding in April 2012. Previously, Mr. Koblish was President and Chief Executive Officer of Orthovita, Inc., a publicly traded orthobiologics and biosurgery medical device company. Mr. Koblish co-founded and currently serves as Chairman of the Board of Onkos Surgical, Inc., a surgical oncology company, and is an operating partner with 1315 Capital, a private investment firm that provides expansion and growth capital to commercial-stage specialty pharmaceutical, medical technology, and health care services companies. Mr. Koblish also serves on the Board of Cerapedics Inc., a private ortho-biologics company, and is a board observer of Spineology, Inc., a private spine company and portfolio company of 1315 Capital. As a Board member of Cerapedics, observer of Spineology, and Chairman of the Board of Onkos Surgical, Mr. Koblish attends one board meeting per quarter, respectively, and as an operating partner for 1315 Capital Mr. Koblish attends one to two meetings per quarter. The remainder of Mr. Koblish's time is dedicated to serving as Chief Executive Officer. Mr. Koblish earned a Master of Science in Engineering degree in Mechanical Engineering and Applied Mechanics from the University of Pennsylvania, and holds a Bachelor of Science degree in Mechanical Engineering from Worcester Polytechnic Institute.
高管简历
中英对照 | 中文 | 英文- Jeffrey Blizard
Jeffrey Blizard，于2022年4月加入董事会，担任董事。Blizard先生是TELA Bio的总裁，这是一种创新的软组织重建解决方案，通过优先保存和恢复患者自身的解剖结构来优化临床结果。在任职于TELA Bio之前，Blizard先生是ABiomed（一家医疗器械技术公司）的外科销售全球主管，该公司在强生的医疗技术部门内作为独立业务运营，他于2017年开始任职。Blizard先生还曾在Abiomed担任销售-CT外科、心力衰竭、ECMO总经理和全国销售总监-CT外科/心力衰竭，在那里他领导了Impella在外科市场的销售。在加入阿比奥梅德之前，Blizard先生曾在美敦力、HeartWare、直觉外科、波士顿科学等知名医疗器械公司担任高级销售领导职务。
Jeffrey Blizard,joined the Board as a Director in April 2022. Mr. Blizard is the President of TELA Bio, an innovative soft tissue reconstruction solution that optimizes clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy. Prior to his role at TELA Bio, Mr. Blizard was the Global Head of Surgical Sales at Abiomed, a medical device technology company that operates as a standalone business within Johnson & Johnson's MedTech segment, where he served beginning in 2017. Mr. Blizard also held positions as General Manager of Sales – CT Surgery, Heart Failure, ECMO, and National Director of Sales – CT Surgery/Heart Failure at Abiomed, where he led sales of Impella in the surgical market. Before joining Abiomed, Mr. Blizard held senior sales leadership roles at renowned medical device companies such as Medtronic, HeartWare, Intuitive Surgical, and Boston Scientific.- Jeffrey Blizard，于2022年4月加入董事会，担任董事。Blizard先生是TELA Bio的总裁，这是一种创新的软组织重建解决方案，通过优先保存和恢复患者自身的解剖结构来优化临床结果。在任职于TELA Bio之前，Blizard先生是ABiomed（一家医疗器械技术公司）的外科销售全球主管，该公司在强生的医疗技术部门内作为独立业务运营，他于2017年开始任职。Blizard先生还曾在Abiomed担任销售-CT外科、心力衰竭、ECMO总经理和全国销售总监-CT外科/心力衰竭，在那里他领导了Impella在外科市场的销售。在加入阿比奥梅德之前，Blizard先生曾在美敦力、HeartWare、直觉外科、波士顿科学等知名医疗器械公司担任高级销售领导职务。
- Jeffrey Blizard,joined the Board as a Director in April 2022. Mr. Blizard is the President of TELA Bio, an innovative soft tissue reconstruction solution that optimizes clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy. Prior to his role at TELA Bio, Mr. Blizard was the Global Head of Surgical Sales at Abiomed, a medical device technology company that operates as a standalone business within Johnson & Johnson's MedTech segment, where he served beginning in 2017. Mr. Blizard also held positions as General Manager of Sales – CT Surgery, Heart Failure, ECMO, and National Director of Sales – CT Surgery/Heart Failure at Abiomed, where he led sales of Impella in the surgical market. Before joining Abiomed, Mr. Blizard held senior sales leadership roles at renowned medical device companies such as Medtronic, HeartWare, Intuitive Surgical, and Boston Scientific.
- Paul Talmo
Paul Talmo，自2023年8月起担任首席技术官。在此之前，Talmo先生自2017年以来在公司担任越来越多的职责，包括担任首席战略官。Talmo先生在医疗设备和服务行业的技术商业化方面拥有超过25年的经验，包括医疗设备、可植入材料以及成像和诊断技术服务。在加入TELA之前，Talmo先生还曾在LifeCell Corporation工作了16年，该公司是一家再生医学公司，于2017年2月被Allergan PLC收购，是将一家专注于烧伤的公司转变为一家软组织重建公司的推动力。Talmo先生负责首先将生物材料引入泌尿妇科市场，用于尿失禁和盆底重建，以及普外科市场，用于疝修补术。Talmo先生还与外科医生密切合作，利用乳房重建领域的第一个生物材料Tela Bio，Inc.开发基于植入物的重建的各种技术和方案，最终在2000年代初将该材料和新技术商业化。Talmo先生拥有新罕布什尔大学工商管理、市场营销、管理和运营文学士学位。
Paul Talmo,has served as Chief Technology Officer since August 2023. Prior to this, Mr. Talmo served in roles of increasing responsibility at the Company since 2017, including serving as Chief Strategic Officer. Mr. Talmo has over 25 years of experience commercializing technologies within the medical device and service industries, including medical devices, implantable materials, as well as imaging and diagnostic technologies services. Prior to joining TELA, Mr. Talmo also spent 16 years at LifeCell Corporation, a regenerative medicine company which was acquired by Allergan plc in February 2017, and was an impetus behind the transformation of a burn focused company into a soft tissue reconstruction company. Mr. Talmo was responsible for first introducing biologic materials to the urogynecology market, for urinary incontinence and pelvic floor reconstruction, as well as the general surgery market, for hernia repair. Mr. Talmo also worked closely with surgeons to develop the various techniques and protocols for implant-based reconstruction with the first biologic material Tela Bio, Inc. ed in breast reconstruction, eventually commercializing the material and new techniques in the early 2000s. Mr. Talmo holds a Bachelor of Arts in Business Administration, Marketing, Management and Operations from University of New Hampshire.- Paul Talmo，自2023年8月起担任首席技术官。在此之前，Talmo先生自2017年以来在公司担任越来越多的职责，包括担任首席战略官。Talmo先生在医疗设备和服务行业的技术商业化方面拥有超过25年的经验，包括医疗设备、可植入材料以及成像和诊断技术服务。在加入TELA之前，Talmo先生还曾在LifeCell Corporation工作了16年，该公司是一家再生医学公司，于2017年2月被Allergan PLC收购，是将一家专注于烧伤的公司转变为一家软组织重建公司的推动力。Talmo先生负责首先将生物材料引入泌尿妇科市场，用于尿失禁和盆底重建，以及普外科市场，用于疝修补术。Talmo先生还与外科医生密切合作，利用乳房重建领域的第一个生物材料Tela Bio，Inc.开发基于植入物的重建的各种技术和方案，最终在2000年代初将该材料和新技术商业化。Talmo先生拥有新罕布什尔大学工商管理、市场营销、管理和运营文学士学位。
- Paul Talmo,has served as Chief Technology Officer since August 2023. Prior to this, Mr. Talmo served in roles of increasing responsibility at the Company since 2017, including serving as Chief Strategic Officer. Mr. Talmo has over 25 years of experience commercializing technologies within the medical device and service industries, including medical devices, implantable materials, as well as imaging and diagnostic technologies services. Prior to joining TELA, Mr. Talmo also spent 16 years at LifeCell Corporation, a regenerative medicine company which was acquired by Allergan plc in February 2017, and was an impetus behind the transformation of a burn focused company into a soft tissue reconstruction company. Mr. Talmo was responsible for first introducing biologic materials to the urogynecology market, for urinary incontinence and pelvic floor reconstruction, as well as the general surgery market, for hernia repair. Mr. Talmo also worked closely with surgeons to develop the various techniques and protocols for implant-based reconstruction with the first biologic material Tela Bio, Inc. ed in breast reconstruction, eventually commercializing the material and new techniques in the early 2000s. Mr. Talmo holds a Bachelor of Arts in Business Administration, Marketing, Management and Operations from University of New Hampshire.
- Antony Koblish
Antony Koblish，是联合创始人之一，自2012年4月创立以来一直担任总裁兼首席执行官和董事会成员。在此之前，Koblish先生是Orthovita医疗的总裁兼首席执行官，该公司是一家上市的骨科生物制剂和生物外科医疗器械公司。Koblish先生与他人共同创立并目前担任外科肿瘤公司Onkos Surgical，Inc.的董事会主席，并且是1315 Capital的运营合作伙伴，1315 Capital是一家私人投资公司，为商业阶段的专业制药、医疗技术和医疗保健服务公司提供扩张和增长资本。Koblish先生还担任私营骨科生物制剂公司Cerapedics Inc.的董事会成员，并且是Spineology，Inc.的董事会观察员，该公司是一家私营脊柱公司，也是1315 Capital的投资组合公司。作为Cerapedics的董事会成员、Spineology的观察员和Onkos Surgical的董事会主席，Koblish先生每季度分别参加一次董事会会议，作为1315 Capital的运营合伙人，Koblish先生每季度参加一到两次会议。Koblish先生剩余的时间专门用于担任首席执行官。Koblish先生获得宾夕法尼亚大学机械工程和应用力学工程学理学硕士学位，并拥有伍斯特理工学院机械工程学理学学士学位。
Antony Koblish,is one of co-founders and has served as President and Chief Executive Officer and as a member of the Board since founding in April 2012. Previously, Mr. Koblish was President and Chief Executive Officer of Orthovita, Inc., a publicly traded orthobiologics and biosurgery medical device company. Mr. Koblish co-founded and currently serves as Chairman of the Board of Onkos Surgical, Inc., a surgical oncology company, and is an operating partner with 1315 Capital, a private investment firm that provides expansion and growth capital to commercial-stage specialty pharmaceutical, medical technology, and health care services companies. Mr. Koblish also serves on the Board of Cerapedics Inc., a private ortho-biologics company, and is a board observer of Spineology, Inc., a private spine company and portfolio company of 1315 Capital. As a Board member of Cerapedics, observer of Spineology, and Chairman of the Board of Onkos Surgical, Mr. Koblish attends one board meeting per quarter, respectively, and as an operating partner for 1315 Capital Mr. Koblish attends one to two meetings per quarter. The remainder of Mr. Koblish's time is dedicated to serving as Chief Executive Officer. Mr. Koblish earned a Master of Science in Engineering degree in Mechanical Engineering and Applied Mechanics from the University of Pennsylvania, and holds a Bachelor of Science degree in Mechanical Engineering from Worcester Polytechnic Institute.- Antony Koblish，是联合创始人之一，自2012年4月创立以来一直担任总裁兼首席执行官和董事会成员。在此之前，Koblish先生是Orthovita医疗的总裁兼首席执行官，该公司是一家上市的骨科生物制剂和生物外科医疗器械公司。Koblish先生与他人共同创立并目前担任外科肿瘤公司Onkos Surgical，Inc.的董事会主席，并且是1315 Capital的运营合作伙伴，1315 Capital是一家私人投资公司，为商业阶段的专业制药、医疗技术和医疗保健服务公司提供扩张和增长资本。Koblish先生还担任私营骨科生物制剂公司Cerapedics Inc.的董事会成员，并且是Spineology，Inc.的董事会观察员，该公司是一家私营脊柱公司，也是1315 Capital的投资组合公司。作为Cerapedics的董事会成员、Spineology的观察员和Onkos Surgical的董事会主席，Koblish先生每季度分别参加一次董事会会议，作为1315 Capital的运营合伙人，Koblish先生每季度参加一到两次会议。Koblish先生剩余的时间专门用于担任首席执行官。Koblish先生获得宾夕法尼亚大学机械工程和应用力学工程学理学硕士学位，并拥有伍斯特理工学院机械工程学理学学士学位。
- Antony Koblish,is one of co-founders and has served as President and Chief Executive Officer and as a member of the Board since founding in April 2012. Previously, Mr. Koblish was President and Chief Executive Officer of Orthovita, Inc., a publicly traded orthobiologics and biosurgery medical device company. Mr. Koblish co-founded and currently serves as Chairman of the Board of Onkos Surgical, Inc., a surgical oncology company, and is an operating partner with 1315 Capital, a private investment firm that provides expansion and growth capital to commercial-stage specialty pharmaceutical, medical technology, and health care services companies. Mr. Koblish also serves on the Board of Cerapedics Inc., a private ortho-biologics company, and is a board observer of Spineology, Inc., a private spine company and portfolio company of 1315 Capital. As a Board member of Cerapedics, observer of Spineology, and Chairman of the Board of Onkos Surgical, Mr. Koblish attends one board meeting per quarter, respectively, and as an operating partner for 1315 Capital Mr. Koblish attends one to two meetings per quarter. The remainder of Mr. Koblish's time is dedicated to serving as Chief Executive Officer. Mr. Koblish earned a Master of Science in Engineering degree in Mechanical Engineering and Applied Mechanics from the University of Pennsylvania, and holds a Bachelor of Science degree in Mechanical Engineering from Worcester Polytechnic Institute.
- Roberto Cuca
Roberto Cuca，曾于2010年3月-2013年8月期间，在一家医药公司- Endo Health Solutions股份有限公司的财务机构担任各种领导职位，包括最近担任的会计和财务高级副总裁。在那之前，他曾于2008年3月-2010年2月期间，在一家专注于医药公司的新兴市场公司- moksha8 Pharmaceuticals股份有限公司担任公司和商业开发总监。2005-2008年期间，曾在JPMorgan Chase公司担任美国医药公司的股权分析师。他是从宾夕法尼亚大学（University of Pennsylvania）Wharton学院获得他的工商管理硕士学位，从Cornell法学院获得他的法学博士学位，以及从Princeton大学获得他的学士学位的。他是一名特许金融分析师凭证持有人。
Roberto Cuca held various leadership positions in the finance organization of Endo Health Solutions Inc., a pharmaceutical company, from March 2010 to August 2013 including, most recently, Treasurer and Senior Vice President, Finance.From 2005 until 2008 he worked at JPMorgan Chase & Co. as an equity analyst covering U.S. pharmaceutical companies. Mr. Cuca received an M.B.A. from the Wharton School of The University of Pennsylvania, a J.D. from Cornell Law School, an A.B. from Princeton University, and he is a CFA charterholder.- Roberto Cuca，曾于2010年3月-2013年8月期间，在一家医药公司- Endo Health Solutions股份有限公司的财务机构担任各种领导职位，包括最近担任的会计和财务高级副总裁。在那之前，他曾于2008年3月-2010年2月期间，在一家专注于医药公司的新兴市场公司- moksha8 Pharmaceuticals股份有限公司担任公司和商业开发总监。2005-2008年期间，曾在JPMorgan Chase公司担任美国医药公司的股权分析师。他是从宾夕法尼亚大学（University of Pennsylvania）Wharton学院获得他的工商管理硕士学位，从Cornell法学院获得他的法学博士学位，以及从Princeton大学获得他的学士学位的。他是一名特许金融分析师凭证持有人。
- Roberto Cuca held various leadership positions in the finance organization of Endo Health Solutions Inc., a pharmaceutical company, from March 2010 to August 2013 including, most recently, Treasurer and Senior Vice President, Finance.From 2005 until 2008 he worked at JPMorgan Chase & Co. as an equity analyst covering U.S. pharmaceutical companies. Mr. Cuca received an M.B.A. from the Wharton School of The University of Pennsylvania, a J.D. from Cornell Law School, an A.B. from Princeton University, and he is a CFA charterholder.